| Name | Title | Contact Details |
|---|
MAXAM Tire North America is a global leader and manufacturer of specialty tires engineered and custom built specifically for OTR, construction, industrial and agricultural industries. MAXAM Tire has over 50+ years experience in designing, distributing and engineering high-quality specialty tires for markets all around the world. When it comes to serving customers, we deliver unmatched business solutions, service and support. Learn more at www.maxamtire.com
WHY CHOOSE BERENSON? Berenson is committed to providing an unmatched customer experience. Thats why we have an industry-leading sample program, same-day shipping to get you your product when you need it, an excellent fulfillment rate, and a wide variety of quality hardware for every budget. Through our three lines, we provide decorative hardware in a range of finishes and designs. From traditional to contemporary, there is something for everyone. We are trend-driven and always updating our collections to keep up with todays styles. Over the years, weve built lasting relationships based on trust, integrity, and mutual respect. As a privately owned family business, our first obligation is to you, our customers. Everyone at Berenson is dedicated to delivering not simply the best products, but the best customer experience — from product selection and delivery through years of satisfaction and enjoyment. Thats our promise to you, every day. Our Vision People pulling together to make Berenson your first choice for visual hardware solutions. Our Mission To provide hassle-free service and unique solutions for your decorative hardware needs.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.